SecBot SecBot
SECBOTREPLAY Home › Report › LGVN

LGVN · Q3 EPS -$1.91, strategic review

Longeveron · PRESS-RELEASE filed Nov 12, 2026 at 16:54 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Nov 12, 2026 at 16:54 ET

Longeveron reported Q3 2026 net loss of $6.1M ($1.91 per share) on revenue of $0.1M, missing the consensus EPS estimate of -$1.70. The ELPIS II Phase 2b trial for HLHS failed its primary endpoint, and the company has initiated a strategic review process with Lucid Capital Markets, exploring a potential sale or merger. Cash stands at $7.2M, expected to fund operations into Q1 2027.

  • Q3 2026 net loss of $6.1M, or $1.91 per share, on revenue of $0.1M
  • EPS of -$1.91 missed consensus of -$1.70 (surprise -12.4%)
  • Revenue declined 16% YoY to $0.1M, in line with consensus of $0.8M? (consensus $800K appears to be annualized or misaligned; actual quarterly revenue $115K)
  • ELPIS II Phase 2b trial for HLHS failed primary endpoint (RVEF at Month 12)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access